<DOC>
	<DOCNO>NCT00142545</DOCNO>
	<brief_summary>The current protocol design satisfy need compassionate use treatment protocol well long-term open label follow-up study .</brief_summary>
	<brief_title>Long Term Safety Efficacy SC Apomorphine Treatment `` Off '' Episodes Late-Stage Parkinson 's Disease</brief_title>
	<detailed_description>The primary objective APO401 gain additional safety data outpatient use apomorphine . APO401 provide opportunity patient participate Mylan-sponsored placebo control trial apomorphine receive apomorphine therapy ambulatory outpatient . Patients enrol Mylan-sponsored study allow participate . Additional data regard safety effectiveness outpatient use subcutaneous apomorphine derive experience .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Prior participation MYLAN sponsor study subcutaneous apomorphine administration treatment Off episode due endofdose motor deterioration ( `` WearingOff '' effect ) sudden loss mobility seemingly random interval ( `` OnOff '' effect ) . With prior approval MYLAN , patient enrol MYLAN sponsor study allow participate . Following approval Amendment 01 , patient meet criteria inclusion , regardless previous participation apomorphine study , allow participate . Age : Adults age &gt; 18 . Sex : Men nonpregnant , nonlactating woman . Women childbearing potential must negative serum ( Beta HCG ) pregnancy test within 14 day study start . Women childbearing potential must use acceptable form contraception . Patients clinical diagnosis idiopathic Parkinson ’ Disease , i.e. , induce drug cause disease . Patients classify stage II V Hoehn Yahr scale stag severity Parkinson 's Disease . Patients refractory motor fluctuation frequency duration . These include necessarily limited patient follow symptom : Immobility result regular dose failure . Severe Off period discomfort . Nocturnal/early morning dystonias . Voiding dysfunction . Swallowing difficulty associate Off period . Off period visual hallucination . Severe biphasic dyskinesia . The patient ( caregiver ) able recognize Off state , sufficiently motivate learn use apomorphine injection control period . The patient ( caregiver ) able maintain OnOff diary . Unless otherwise specify , enrol patient must optimally maximize oral therapy regimen . Optimized oral antiPD medication include : levodopa/carbidopa either immediate delayed release form , plus least one direct act oral dopamine agonist least 30 day prior enrollment study . Patients medical therapy clinically significant psychosis dementia relate ingestion antiPD medication . ( Patients hallucination central adverse reaction associate solely antiPD medication exclude . ) Patients history drug alcohol dependency within one year prior study enrollment . Patients unstable clinically significant disease cardiovascular ( include orthostatic hypotension ) , hematologic ( include Coombs ’ positive hemolytic anemia ) , hepatic , renal , metabolic , respiratory , gastrointestinal endocrinological system neoplasm within three month start study . Patients history true allergy morphine derivative ( include apomorphine ) , sulfur , sulfur contain medication , sulfites , sulfate , Tigan ( R ) ( trimethobenzamide ) . Patients treat experimental agent ( apomorphine intermittent subcutaneous injection ) within 30 day study entry . Patients participation Berteksponsored study APO202 exclude participation study . Patients whose apomorphine regimen characterize administration method intermittent subcutaneous injection . Patients could would sign Informed Consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
</DOC>